SQZ Biotechnologies Company (SQZB)

0.0210 0.0000 (0.00%) At close: 03:23PM EDT

SQZ Biotechnologies Company

200 Arsenal Yards Boulevard
Suite 210
Watertown, MA 02472
United States
617 758 8672
https://www.sqzbiotech.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 53

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Howard Bernstein M.D., Ph.D.	Interim CEO & Director	552.14k	N/A	1957
Mr. Lawrence J. Knopf Esq.	General Counsel & Secretary	512.38k	N/A	1962
Dr. Marshelle Smith Warren M.D.	Chief Medical Officer	476.27k	N/A	1964
Dr. Robert S. Langer Jr., Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1949
Mr. Richard V. Capasso CPA	Chief Accounting Officer	N/A	N/A	1962
Mr. David First	Chief People Officer	N/A	N/A	1964
Ipsita Roymoulik Ph.D.	Senior Vice President of CMC & QUALITY	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Corporate Governance

SQZ Biotechnologies Company’s ISS Governance QualityScore as of May 1, 2024 is 8. The pillar scores are Audit: 4; Board: 7; Shareholder Rights: 9; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.